Background/Aims: The main pathogenic mechanism of diabetes is a decrease in the number of islet beta cells or a decline in their function. Recent studies have shown that pancreatic long noncoding RNAs (lncRNAs) have a high degree of tissue specificity and may be involved in the maintenance of islet cells function and the development of diabetes. The aim of this study was to investigate the molecular regulatory mechanism of mouse maternal expressed gene 3 (Meg3) in insulin biosynthesis in pancreatic islets. Methods: Chromatin immunoprecipitationquantitative polymerase chain reaction (qPCR) and RNA immunoprecipitation-qPCR were used to investigate the molecular mechanism of lncRNA Meg3 in insulin biosynthesis by regulating v-Maf musculoaponeurotic fibrosarcoma oncogene family, protein A (MafA), a mature beta cell marker in the MIN6 beta cell line. Further, the expression levels of Meg3, Ezh2, MafA, Rad21, Smc3, and Sin3α were analyzed in vivo and in vitro by RT-PCR and western blotting. Results: Intranuclear lncRNA Meg3 can bind EZH2, a methyltransferase belonging to the Polycomb repressive complex-2, in pancreatic islet cells. In addition, knockdown of Ezh2 can also inhibit the expression of MafA and Ins2, while expression levels of Rad21, Smc3, and Sin3α are upregulated, by interfering with Ezh2 or Meg3 in pancreatic beta cells. Knockdown of Meg3 resulted in the loss of EZH2 binding and H3K27 trimethylation occupancy of Rad21, Smc3, and Sin3α promoter regions. The inhibition of Rad21, Smc3, or Sin3α, which directly act on the MafA promoter, leads to upregulated expression of MafA in both MIN6 cells and mouse islets. Moreover, the synthesis and secretion of insulin were increased by inhibition of these transcription factors. Conclusions: Pancreatic lncRNA Meg3 can epigenetically regulate the expression of Rad21, Smc3, and Sin3α via EZH2-driven H3K27 methylation. By inhibiting the expression of Rad21, Smc3, or Sin3α, Meg3 promotes the expression of MafA and affects the production of insulin.
Introduction
Synthesis and secretion of insulin are the main functions of pancreatic beta cells. Beta cell dysfunction or mass reduction appears in almost all types of diabetes mellitus and thus eventually leads to insulin deficiency [1] . The biosynthesis of insulin is regulated by many transcription factors, such as v-Maf musculoaponeurotic fibrosarcoma, oncogene family, protein A (MafA) [2] [3] [4] [5] , neurogenic differentiation1 (NeuroD1) [6, 7] , and pancreatic and duodenal homeobox 1 (PDX1) [8, 9] . The transcriptional activator MafA, which regulates insulin transcription in response to circulating glucose levels, is expressed in mature pancreatic beta cells [2, 3, 10, 11] . It is essential for the maintenance of islet structure and function [12] and the expression of MafA is regulated by long noncoding RNAs (lncRNAs) [13, 14] . Studies have shown that expression of lncRNAs may influence susceptibility to diabetes [15, 16] . lncRNAs, located in the nucleus or cytoplasm, are generally more than 200 nucleotides and do not encode a functional protein. They regulate a number of biological processes, such as cell proliferation and apoptosis. Notably, studies have demonstrated that lncRNAs are also implicated in many human diseases [17] [18] [19] . Ferrer et al. found human pancreatic lncRNAs with high tissue specificity. Depletion of the beta cell-specific lncRNA HI-LNC25 may significantly downregulate the expression of the diabetes susceptibility gene GLIS3 [16] , which increases the risk of both type 1 and type 2 diabetes [20] . The lncRNAs maternally expressed gene 3 (Meg3) [13] and taurine upregulated gene 1(TUG1) [14] are associated with the maintenance of pancreatic beta cell function.
MEG3 is located on human chromosome 14q32.3 and encodes an lncRNA. In the mouse, it is also known as gene trap locus 2 (Gtl2), and is located at the distal chromosome 12 [21, 22] . Microarray analysis indicates that MEG3 expression is 20-fold higher in human beta cells compared with alpha cells [23] and is downregulated in type 2 diabetes donor islets [15] . belonging to the imprinted DLK1-MEG3 gene region, has strong homology in humans and mice. RNA expressions from the DLK1-MEG3 locus are determined by the methylation of two differentially methylated regions (DMRs), ''IG-DMR'' and ''MEG3-DMR''. The "MEG3-DMR" is located 1.5 kb upstream of the transcription initiation site of MEG3, and overlaps with the MEG3 promoter. Methylation of this region is increased in type 2 diabetes islets [15] . Further, genome-wide association studies revealed that this region alters susceptibility to type 1 diabetes [24] . In addition, we found that Meg3 was downregulated in pancreatic islets of type 1 (NOD) and type 2 (db/db) diabetic mice. All of these findings show that lncRNA Meg3 is essential for the proper function of pancreatic islets. In MIN6 cells and mouse pancreatic islets, Meg3 expression is dynamically regulated by glucose, and the suppression of Meg3 leads to reduced expression of the transcription factors MafA [13] , although the molecular mechanisms remain unknown.
In this study, we demonstrated the mechanism of MafA regulation by lncRNA Meg3 in mouse pancreatic beta cells. Through bioinformatics analysis, we found the inhibitory factors RAD21 cohesin complex component (Rad21), structural maintenance of chromosomes 3 (Smc3), and transcriptional regulator SIN3A (yeast) (Sin3α), which bind to the promoter of MafA. Further, we examined the role of Meg3 in the regulation of these inhibitory factors through EZH2. These findings improve understanding of the mechanism of insulin biosynthesis and provide novel insight into the pathogenesis of diabetes.
Materials and Methods

Islet isolation and culture
The Ethics Committee for the use of Experimental Animals at Nanjing Medical University approved all the animal experiments. Mouse pancreatic islets were isolated, handpicked as previously described [25] from NOD male mice, db/db male mice (Model Animal Research Center of NJU, Nanjing, Jiangsu, China), Balb/c male mice, and C57BL/6J male mice(8 weeks old; 20-23 g; Experimental Animal Center of Nanjing Medical University, Nanjing, Jiangsu, China).
MIN6 cell culture
The murine insulin-secreting cell line Min6 was cultured in DMEM (Invitrogen) containing 25 mM D-glucose, 10 mM HEPES , 50 mM sodium pyruvate, supplemented with 15% FBS, 100 U/ mL penicillin, 100 mg/mL streptomycin, and 50 mmol/L β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA). Cells were planted at a density of 5×10 5 /cm 2 for RNA isolation and 10
5
/cm 2 for insulin secretion.
RNA interference in vitro and in vivo
Small interfering (si) RNA was synthesized from Realgene and transfected to cells for 48 h by InstantFECT transfection reagent (PGR-Solutions Inc., Bridgeville, PA, USA). The mock group was set by cells cultured with the transfection reagent alone, and scrambled siRNA was used as negative control (si-NC). According to the instruction manual, the final concentration of siRNA was 100 nmol/L. siRNA delivery in vivo by hydrodynamic injection has been described in our recent study [26] . The siRNA sequences are listed in Table 1 .
Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was extracted using TRIzol reagent (Invitrogen) from mouse islets and MIN6 cells. RNA (1 μg) was reverse-transcribed to cDNA using a Reverse Transcription Kit (Takara, Dalian, China). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analyses were performed using SYBR Premix Ex Taq (Takara). Gene expression was determined with normalization to mouse 18S ribosomal RNA expression by 2 -DDCt methodology. The primer sequences are listed in Table 1 .
Subcellular fractionation location
According to the manufacturer's instructions, nucleocytoplasmic separation was performed using the PARIS Kit (Life Technologies).
Western blot analysis
After determining the protein content of mouse islets and Min6 cells, Western blotting was performed as described previously [27] . The blot was probed with antibody: anti-MafA (sc-66958, Santa Cruz Biotechnology, CA), anti-Rad21 (ab992, Abcam), anti-SMC3 (ab9263, Abcam), anti-Sin3α (ab3479, Abcam), and anti-β-Actin (#4970, Cell Signaling Technology, MA). The secondary antibody was from Beijing Zhong Shan Biotechnology CO (Beijing, China). Chromatin immunoprecipitation (ChIP) According to the manufacturer's instruction, ChIP assays were performed using an EZ-ChIP kit (Millipore, USA). For immunoprecipitation, 5 μg of rabbit antibody anti-Rad21 (ab992, Abcam), anti-SMC3 (ab9263, Abcam), anti-Sin3α (ab3479, Abcam), anti-EZH2 (#5246, Cell Signaling Technology), H3 trimethyl Lys 27 antibody (Millipore, USA), or normal rabbit IgG (Millipore) was used, and DNA quantification was performed by qPCR with SYBR Green Mix (Takara). All primers for genes promoters are described in Table 1 .
RNA immunoprecipitation (RIP)
According to the manufacturer's instructions, RIP assays were performed using Magna RIP™ RNABinding Protein Immunoprecipitation Kit (Millipore) and 5 μg of the antibody anti-EZH2 (no.17-662, Millipore).
Glucose stimulated insulin secretion (GSIS)
Min6 cells were planted in 24-well plates at 10 5 per well. At 48 h posttransfection, the medium was removed and cells were washed twice with sterile Krebs Ringer buffer (KRB) (115 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 20 mM NaHCO 3 , 16 mM HEPES, 2.56 mM CaCl 2 , and 0.2% bovine serum albumin [BSA]) followed by pre-incubation with 200 ml of the same buffer supplemented with 2 mM glucose at 37 °C for 1 h. Subsequently, the cells were treated for 1 h in 200 µl KRB buffer containing with low (2 mM) or high (20 mM) concentrations of glucose. Supernatants were collected at the indicated time and insulin concentrations were determined using radioimmunoassay (RIA) as previously described [28] . After transfection for 48 h (at 25 mM glucose), cellular insulin content was detected after acid ethanol extraction (0.15 M HCl in 75% ethanol). These results were normalized to the total protein concentration as previously described [13, 29, 30] . Subsequently, the amount of secreted insulin protein was counted (as a ratio) in comparison with the total cellular insulin content in the experiment.
Statistical analysis
The data are presented as mean ± SEM. Statistical significances (p＜0.05), which are indicated in the figures, were performed using a two-tailed paired Student's t-test, or analysis of variance (ANOVA) for more than two groups comparison (GraphPad Prism 5, San Diego, California, USA).
Results
lncRNA Meg3 regulates expression of MafA through EZH2 in pancreatic beta cells
To investigate the possible mechanism of lncRNA Meg3 regulation of MafA in beta cells, it was necessary to define the intracellular localization of Meg3. Meg3 expression was measured in nuclear and cytosolic fractions from MIN6 cells by qRT-PCR, and the differential enrichments of U1 and Gapdh RNA were used as fractionation indicators. We found a considerable increase in the expression of Meg3 in the nucleus relative to the cytosol (Fig.  1A) , which suggested that Meg3 is primarily localized in the nucleus and plays a regulatory role in the levels of transcription. Numerous lncRNAs (HOTAIR, MALAT1, EBIC, H19, ANRIL, etc.) have been confirmed to regulate the expression of target genes via EZH2-driven H3K27 methylation [31] [32] [33] [34] . EZH2, a methyltransferase belonging to the core component of the Polycomb repressive complex-2 (PRC2), is responsible for the trimethylation of lysine 27 in histone H3 (H3K27me3) [35] . EZH2 photoactivatable-ribonucleotide-enhanced crosslinking and immunoprecipitation (PAR-CLIP) data [36] revealed that EZH2 interacted with 165 lncRNAs, including Meg3, in mouse embryonic stem cells (mESCs) [37, 38] . Therefore, we examined whether the lncRNA Meg3 plays a role in islet beta cells by binding to EZH2. As shown in Fig. 1B , endogenous Meg3 was enriched in the anti-EZH2 RNA immunoprecipitation (RIP) fraction relative to the IgG fraction in MIN6 cells. Endogenous Gapdh was used as a negative control. Thus, lncRNA Meg3 plays a role in pancreatic beta cells as well as in mESCs by binding to EZH2. Moreover, we transfected siRNA to knockdown Ezh2 in both MIN6 cells and pancreatic islets. The knockdown efficiency of Ezh2 is shown in Fig. 1C ; the si-Ezh2 group was a mixture of two interfering sequences. Because the interference efficiency of the si-Ezh2 group was highest, this interference was adopted in the following experiments.
The results were consistent with the inhibition of Meg3 in previous studies. The expression levels of MafA and Ins2 (Meg3 primarily affects the expression of Ins2 [13] )were significantly reduced by Ezh2 inhibition in both MIN6 cells and pancreatic islets (Fig. 1D, E) . The same result for MafA was observed at the protein level (Fig. 1F ). These findings indicate that lncRNA Meg3 regulates MafA expression through binding EZH2 in pancreatic beta cells.
lncRNA Meg3 and EZH2 negatively regulate Rad21, Smc3, and Sin3α expression
It is clear that MafA is essential for the maintenance of islet structure and the function of beta cells [2, 12, 39, 40] . The expression of Ins2 was significantly downregulated in MIN6 cells by MafA inhibition (Fig. 2A) . The knockdown efficiency of MafA is shown in Fig. 2B ; the si-MafA group was a mixture of two interfering sequences. The Caltech transcription factor binding site (TFBS), PSU TFBS, and Stan/Yale TFBS ChIP-sequences (http://genome.ucsc. edu/) showed binding of transcription factors to the MafA promoter region in various cells (Table 2) . Based on the mechanism of EZH2, we needed to find the transcription factors that negatively regulate MafA. Thus, we inhibited Meg3 and Ezh2 in MIN6 cells and detected the expression of these transcription factors (Fig. 2C) . The knockdown efficiency of Meg3 is shown in Fig. 2D ; the si-Meg3 group was a mixture of two interfering sequences. The results show that the expression levels of Rad21, Smc3, and Sin3α consistently increased in the two conditions. In addition, the same results were obtained after repeated experiments in pancreatic islet cells (Fig. 2E, F) . Western blotting assays also confirmed that the expression levels of Rad21, Smc3, and Sin3α were significantly higher compared to the control groups in MIN6 cells and pancreatic islets after knockdown of Meg3 or Ezh2 (Fig. 2G) . These results suggest that Meg3 downregulated the expression of Rad21, Smc3, and Sin3α in pancreatic beta cells through EZH2.
lncRNA Meg3 epigenetically regulates the expression of Rad21, Smc3, or Sin3α by binding EZH2 To clarify the mechanism of Meg3 regulation of the three transcription factors, we examined whether EZH2 was bound to the promoter region of Rad21, Smc3 or Sin3α, 
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As shown in Fig. 3 , after transfection with siRNA of Meg3 for 48 h in MIN6 cells, EZH2 was bound to the promoters of Rad21, Smc3, and Sin3α, and we detected H3K27 trimethylation using ChIP-qPCR. Knockdown of Meg3 resulted in the loss of EZH2 binding (Fig. 3A-C) and H3K27 trimethylation occupancy of the Rad21, Smc3, and Sin3α promoters (Fig. 3E-G) , and no difference was detected at the promoter of Hoxa9, a known EZH2-targeted gene [41] (Fig.  3D, H) . Our results suggest that lncRNA Meg3 binds to EZH2 via trimethylation of H3K27 in the Rad21, Smc3, and Sin3α promoter, and in turn suppresses the expression of these transcription factors.
Rad21, Smc3 or Sin3α can bind to the MafA promoter and negatively regulates MafA expression in pancreatic islets
Rad21 and Smc3, two core subunits of cohesin [42] , are crucial for chromosome segregation and DNA repair [43, 44] . Sin3α can recruit histone deacetylases (HDACs) to the proximal promoter and repress target gene expression [45, 46] . However, there have been no reports regarding their regulation of MafA. It is known that Rad21, Smc3, and Sin3α can bind to the promoter region of MafA in a variety of cells, but whether these transcription factors can bind to the MafA promoter in the islet cells is not clear. To determine whether they can bind to the MafA promoter region, we used ChIP-qPCR to analyze the process in MIN6 cells. The results show that Rad21, Smc3, and Sin3α have a higher degree of promoter binding compared with the level of recruitment of IgG on the MafA promoter (Fig. 4A-C) . This suggests that these three transcription factors can directly bind to the promoter region of MafA in pancreatic islet cells, and Meg3 silencing correlates with enhanced recruitment (Fig. 4D, E) . Using western blotting assays, we also found that MafA protein level was upregulated by Rad21, Smc3, or Sin3α inhibition (Fig. 4F) . The knockdown efficiency of Rad21, Smc3, and Sin3α is shown in Fig. 4G , J; the si-Rad21, siSmc3 and si-Sin3α groups were a mixture of two interfering sequences. From these findings, we determined that Rad21, Smc3, or Sin3α can inhibit the expression of MafA.
Suppression of Rad21, Smc3, or Sin3α expression in MIN6 cells increases insulin synthesis and secretion through MafA
To determine whether Rad21, Smc3 or Sin3α regulates the synthesis and secretion of insulin through MafA, we used siRNA targeting knockdown of Rad21, Smc3, or Sin3α in MIN6 cells. After the transfection of siRNA into MIN6 cells for 48 h, qRT-PCR analysis revealed that Ins2 expression was significantly increased in the si-Rad21, si-Smc3 and si-Sin3α groups (Fig. 5A) . Taking into account that the synthesis of insulin can affect insulin secretion [47] , we detected GSIS of MIN6 cells after Rad21, Smc3, or Sin3α inhibition. We found no significant changes in insulin release at a glucose level of 2 mM but, compared with the control group, the secretion of insulin was markedly increased at a glucose level of 20 mM after knockdown of Rad21, Smc3, or Sin3α (Fig. 5B) . The results show that the loss of Rad21, Smc3, or Sin3α can promote the synthesis and secretion of insulin in MIN6 cells. Further, we analyzed whether Rad21, Smc3, and Sin3α were abnormally expressed in diabetic mice. Primary islets were isolated from two types of diabetic mice, NOD and db/db. qRT-PCR analysis showed that the expression levels of Rad21, Smc3, and Sin3α were increased in the two mouse models. By contrast, the expressions of Meg3, Ezh2, MafA, and Ins2 were reduced in diabetic pancreatic islets (Fig. 5C) . Furthermore, after treating MIN6 cells with tumor necrosis factor alpha (TNFα) for 24 h and 48 h, we obtained similar results to those observed in the two types of diabetic mice (Fig. 5D ). These findings also suggest that Meg3 can influence MafA expression and insulin production by modulating Rad21, Smc3, or Sin3α in mouse pancreatic islets.
Downregulation of Meg3 increases expression of Rad21, Smc3, and Sin3α in vivo
We used the intravenous hydrodynamic method for administering siRNA in normal Balb/c male mice. After isolation and purification of mouse pancreatic islets, we examined the expression of MafA, Rad21, Smc3, and Sin3α by qRT-PCR and western blotting (Fig. 6A, B) . The results showed that expression levels of Rad21, Smc3 and Sin3α were increased by the inhibition of Meg3 in mouse pancreatic islets, and MafA expression was reduced at both the nucleic acid and protein levels. Similarly, the expression of Ins2 was significantly decreased at the nucleic acid level in vivo (Fig. 6A) . These results further confirm our findings with the MIN6 cell line and mouse primary islet cells. ; a representative of three experiments is shown. si-Rad21, si-Smc3 or si-Sin3α group was a mixture of two interfering sequences. Beta actin protein was used as an internal control. ***, P<0.001; **, P<0.01; *, P<0.05; two-tailed unpaired Student t test. Error bars, mean ± SEM of three independent experiments. 
Discussion
Increasing evidence suggests that lncRNAs are associated with biological activities. lncRNAs have been shown to play a central role in physiology and human diseases [19] , and numerous lncRNAs are expressed in a specific manner in different tissues and cells. With further research, lncRNAs have been shown to correlate with the function of pancreatic islets [13, 14] and the occurrence of diabetes [15, 16] . However, there have been few studies on the molecular mechanism of lncRNAs in pancreatic islets.
In this study, we investigated the molecular mechanism of the lncRNA Meg3 and its influence on insulin synthesis by regulating the expression of the key transcription factor MafA in pancreatic beta cells. Pancreatic Meg3, encoded by the imprinted Dlk1-Meg3 gene region, was associated with the function of beta cells. According to the preliminary results, the expression of Meg3 was significantly downregulated in the islets of diabetic mice. Further, its deletion can result in the decrease of MafA and insulin in beta cells [13] . MafA, a key transcription factor, binds to the RIPE3b/C1 element of the insulin promoter [2] and principally regulates insulin biosynthesis and secretion [40, 48] . Deficiency of MafA is closely related to the occurrence of diabetes [49, 50] . Thus, we speculate that lncRNA Meg3 can influence the expression of insulin by regulating MafA. However, the molecular mechanism of Meg3 regulation of MafA in pancreatic islets is not clear.
An increasing number of studies have found that lncRNAs can regulate downstream target genes by binding to EZH2 in the nucleus. EZH2, a methyltransferase belonging to PRC2, can initiate trimethylation at lysine 27 in histone H3 [35] . Moreover, research has confirmed that MEG3 can regulate target gene expression by recruiting EZH2 in human breast cells [38] . Using PAR-CLIP, Kaneko et al. revealed that Meg3 can bind to EZH2 in mESCs. In addition, Meg3 RNA directs EZH2 to suppress transcription of Dlk1 in mESCs [51] . To clarify the mechanism of Meg3 regulation, we first determined the localization in pancreatic beta cells. By observing the subcellular localization, we found that Meg3 was primarily expressed in the nucleus and, as previously reported [37] , can bind to EZH2 in MIN6 cells. Thus, pancreatic Meg3 can epigenetically inhibit the expression of target genes at the transcriptional level by binding EZH2 in the nucleus. Similar to the effects of Meg3 knockdown on MafA expression, the expression of MafA was reduced after inhibiting Ezh2 in MIN6 cells and pancreatic islets. According to the mechanism of Meg3 regulation of target genes through EZH2, we needed to find the negative transcription factors of MafA. Through the Caltech TFBS, PSU TFBS, and Stan/Yale TFBS ChIP-sequences, we found a number of transcription factors bound to the MafA promoter. After screening in MIN6 cells and pancreatic islets, we found that expression of Rad21, Smc3, and Sin3α was negatively regulated by Meg3. Rad21 and Smc3 are two core subunits of cohesin, and are associated with chromosome segregation and DNA repair [43, 44] . Moreover, Sin3α suppresses the expression of the target gene by recruiting HDACs to deacetylate histones H3 and H4 of the proximal promoter [45] . An intrauterine growth retardation state has been linked to the onset of type 2 diabetes in adulthood, along with the recruitment of Sin3α and HDAC1 to the promoter of Pdx1 [46] . Through ChIP-qPCR analysis, we determined that Meg3 can act directly on the Rad21, Smc3, or Sin3α promoter by binding EZH2, and inhibit the transcription of these genes by H3K27 trimethylation. We have demonstrated that lncRNA Meg3 can be directly responsible for the negative regulation of Rad21, Smc3, and Sin3α. However, whether they can negatively regulate MafA remains to be studied.
To confirm that Rad21, Smc3 and Sin3α are negative regulators of MafA, we first investigated whether they were bound to the MafA promoter in pancreatic beta cells. ChIPqPCR analysis was used to detect the recruitment of Rad21, Smc3, or Sin3α in the MafA promoter region, and we found that the recruitment of the three transcription factors in the MafA promoter was significantly higher than in the IgG group in MIN6 cells. In addition, Meg3 silencing correlated with enhanced recruitment of Rad21, Smc3 or Sin3α to the MafA promoter. These results indicate that Rad21, Smc3 or Sin3α can also be directly bound to the promoter of MafA in mouse beta cells. Additionally, as the expression of Meg3 is Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry downregulated, the recruitment of these transcription factors on the MafA promoter is enhanced. To prove that Rad21, Smc3, or Sin3α can negatively regulate the expression of MafA, we interfered with the expression of these transcription factors in MIN6 cells and pancreatic islets by siRNA, and then determined the expression of MafA at both the nucleic acid and protein levels. If Rad21, Smc3 and Sin3α negatively regulate the expression of MafA, their inhibition will promote the expression of MafA. The subsequent results confirmed our hypothesis. By specific interference of these transcription factors, the expression of MafA was upregulated in MIN6 cells and pancreatic islet cells. Moreover, in the rescue experiment, the expression of MafA was downregulated by inhibition of Meg3, and subsequent to the inhibition of Ras21, Smc3, or Sin3α in MIN6 cells, the expression of MafA was restored at the nucleic acid and protein levels (data not shown). MafA is an important transcription factor regulating the expression of insulin. Upregulated expression of MafA can promote the synthesis and secretion of insulin, and play a pivotal role in the function of islet cells. We believe that if Rad21, Smc3 or Sin3α negatively regulates the expression of MafA, then inhibiting their expression, which promotes the upregulated expression of MafA, should also promote the synthesis and secretion of insulin. Therefore, we examined the synthesis and secretion of insulin by inhibiting Rad21, Smc3, or Sin3α in MIN6 cells. We found that the expression of insulin was increased after interfering with these transcription factors, which was consistent with the expression of MafA. In addition, insulin secretion was higher in the presence of 20 mM glucose after Rad21, Smc3, or Sin3α knockdown compared with the control in MIN6 cells. Therefore, the experimental results are consistent with our proposal; after the suppression of these transcription factors, the synthesis and secretion of insulin was significantly increased. Thus, we determined the negative regulatory effect of Rad21, Smc3, and Sin3α on MafA in mouse pancreatic islets, and their effect on the synthesis and secretion of insulin by inhibiting MafA. Overall, our findings show the molecular mechanism of lncRNA Meg3 in regulating MafA in pancreatic beta cells. Pancreatic Meg3 suppresses the MafA negative regulating transcription factors Rad21, Smc3 or Sin3α by methylation of EZH2, which upregulates the expression of MafA, and promotes the synthesis and secretion of insulin. Interestingly, in two types of diabetic mice (NOD and db/db), the expression of these transcription factors was significantly increased, whereas the expressions of MafA, Ins2, Meg3, and Ezh2 were markedly decreased. After treating MIN6 cells with TNFα, a major pro-inflammatory cytokine associated with the occurrence of diabetes, the expression of these genes was measured and the results were consistent with the two types of diabetic mice. In addition, we validated the results observed in cells in vivo and obtained consistent results. These results confirm that Meg3 plays an important role in the function of mouse islets, by binding EZH2 to regulate downstream target genes, thus affecting the synthesis of insulin.
Conclusion
We have demonstrated the mechanism of Meg3 regulation of pancreatic beta cells function. Our findings add to the current understanding of the regulatory mechanism of islet cell function and the possible mechanism of the development of diabetes. We will assess whether the same mechanisms operate in diabetic mice and humans in future studies.
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